FGF2 and chronic myelogenous leukemia, BCR-ABL1 positive: The production of fibroblast growth factor 2 (FGF2) by BM-derived MSCs and the decreased level of reactive oxygen species (ROS) in CML LSCs also increases TKI resistance [88, 89].